Center researchers have been leaders in the nation’s two premier programs for active monitoring of the safety of licensed vaccines: the FDA Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program, part of the FDA Mini-Sentinel program, and the CDC Vaccine Safety Datalink project. Center investigators have also led major studies to address the problems of antibiotic resistance related to vaccination. Examples of projects include:
- Conducting broad safety assessments of COVID-19 and other approval vaccines using tree-based scan statistics
- Studying the risk of Kawasaki disease after PCV13 vaccination
- Developing a framework for studying vaccine safety in pregnant women using health plan, birth registry and fetal death registry data
- Establishing the data and methodologic infrastructure for active surveillance of vaccine and drug safety
- The Study of Pneumococcal Antibiotic Resistance in Children (SPARC), one of the largest longitudinal studies of colonization with pneumococcus, a major cause of disease in children worldwide. It includes investigations of the impact of newly introduced vaccines on carriage, disease, and resistance, as well as genetic analyses of this rapidly adapting organism with important ramifications for human health.
Related News and Recent Publications
- Kamidani S, Panagiotakopoulos L, Licata C, Daley MF, Yih WK, Zerbo O, Tseng HF, DeSilva MB, Nelson JC, Groom HC, Williams JTB, Hambidge SJ, Donahue JG, Belay ED, Weintraub E. Kawasaki disease following the 13-valent pneumococcal conjugate vaccine and rotavirus vaccines. Pediatrics. 2022. In press.
- Nelson JC, Ulloa-Pérez E, Yu O, Cook AJ, Jackson ML, Belongia EA, Daley MF, Harpaz R, Kharbanda EO, Klein NP, Naleway AL, Tseng HF, Weintraub ES, Duffy J, Yih WK, Jackson LA. Active post-licensure safety surveillance for recombinant zoster vaccine using electronic health record data. Am J Epidemiol. 2022. In press.
- Yih WK and Maro JC. Tree-based data-mining for COVID-19 vaccine safety assessment in the Vaccine Safety Datalink (VSD). Protocol. Available at: https://www.cdc.gov/vaccinesafety/pdf/covid19-rca-protocol-1350-508.pdf.
- Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the recombinant herpes zoster vaccine. Am J Epidemiol. 2022;191:957-64.
- Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the 9-valent human papillomavirus vaccine. Am J Epidemiol. 2021;190:1253-9.
- Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, Xu S, Yih WK, Glanz JM, Williams JTB, Hambidge SJ, Lewin BJ, Shimabukuro TT, DeStefano F, Weintraub ES. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390-9.
- Baker MA, Jankosky C, Yih WK, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, DeLuccia S, Lin ND, McMahill-Walraven CN, Menschik D, Selvan MS, Selvam N, Tilney RC, Zichittella L, Lee GM, Kawai AT. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Vaccine. 2020;38:2166-71.
- Baker MA, Baer B, Kulldorff M, Zichittella L, Reindel R, DeLucciaS, Lipowicz H, Freitas K, Jin R, Yih WK. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLoS Medicine. 2019;16:e1002844.
For more information on the Center's work please contact Ryan Walsh